MX2020003132A - Anticuerpos anti-ctla4 y usos de los mismos. - Google Patents

Anticuerpos anti-ctla4 y usos de los mismos.

Info

Publication number
MX2020003132A
MX2020003132A MX2020003132A MX2020003132A MX2020003132A MX 2020003132 A MX2020003132 A MX 2020003132A MX 2020003132 A MX2020003132 A MX 2020003132A MX 2020003132 A MX2020003132 A MX 2020003132A MX 2020003132 A MX2020003132 A MX 2020003132A
Authority
MX
Mexico
Prior art keywords
ctla4 antibodies
ctla4
antibodies
ctla
lymphocyte
Prior art date
Application number
MX2020003132A
Other languages
English (en)
Inventor
Fang Yang
Yi Yang
Yanan Guo
Xiaodong Cheng
Yunyun Chen
Jingshu Xie
Chunyan Dong
Chengyuan Lu
Yuelei Shen
Jian Ni
Original Assignee
Eucure Beijing Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eucure Beijing Biopharma Co Ltd filed Critical Eucure Beijing Biopharma Co Ltd
Publication of MX2020003132A publication Critical patent/MX2020003132A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Esta descripción se refiere a anticuerpos de la proteína 4 asociada a linfocitos T anti-citotóxicos (CTLA4 o CTLA-4), fragmentos de unión al antígeno y los usos de los mismos.
MX2020003132A 2017-09-21 2017-09-21 Anticuerpos anti-ctla4 y usos de los mismos. MX2020003132A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/102816 WO2019056281A1 (en) 2017-09-21 2017-09-21 ANTI-CTLA4 ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020003132A true MX2020003132A (es) 2020-07-28

Family

ID=65810881

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003132A MX2020003132A (es) 2017-09-21 2017-09-21 Anticuerpos anti-ctla4 y usos de los mismos.

Country Status (12)

Country Link
US (3) US11034764B2 (es)
EP (1) EP3684812A4 (es)
JP (2) JP7155270B2 (es)
KR (1) KR102543719B1 (es)
CN (1) CN111406069B (es)
AU (1) AU2017432728B2 (es)
BR (1) BR112020005496A2 (es)
CA (1) CA3073984A1 (es)
IL (2) IL272993A (es)
MX (1) MX2020003132A (es)
SG (1) SG11202001604UA (es)
WO (1) WO2019056281A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
CA3073984A1 (en) 2017-09-21 2019-03-28 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4 antibodies and uses thereof
CA3084394A1 (en) 2017-11-24 2019-05-31 Eucure (Beijing) Biopharma Co., Ltd Anti-ox40 antibodies and uses thereof
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
WO2021098851A1 (en) * 2019-11-20 2021-05-27 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4/ox40 bispecific antibodies and uses thereof
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 包含il-7變體之雙官能分子
US12559565B2 (en) * 2020-04-13 2026-02-24 Biosion Inc. Antibodies binding CTLA4 and uses thereof
CN111789954B (zh) * 2020-09-08 2020-12-15 北京百奥赛图基因生物技术有限公司 延缓衰老的方法和药物
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022169269A1 (ko) * 2021-02-03 2022-08-11 주식회사 유틸렉스 항 ctla-4 항체 및 이의 용도
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
CN112921005B (zh) * 2021-04-14 2023-07-07 中国农业科学院兰州兽医研究所 一株杂交瘤细胞株及其产生的犬细小病毒vp2蛋白单克隆抗体和应用
CN113754770B (zh) * 2021-10-21 2023-11-03 江苏诺迈博生物医药科技有限公司 一种特异性结合人ctla4的抗体及包含其的药物和试剂盒
EP4532556A4 (en) * 2022-06-01 2026-06-17 Syncromune Inc CANCER TREATMENT METHOD BY LYSIS OF TUMOR CELLS AND INTRATUMORAL ADMINISTRATION OF COMBINATIONS OF IMMUNOTHERAPEUTIC INGREDIENTS
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
EP4565610A1 (en) 2022-08-02 2025-06-11 Ose Immunotherapeutics Multifunctional molecule directed against cd28
CN120019078A (zh) * 2022-09-02 2025-05-16 西奇利德股份有限公司 抗ctla-4单克隆抗体及其用途
EP4628505A1 (en) * 2022-10-28 2025-10-08 Genor Biopharma Co., Ltd. Novel anti-ctla4 antibody
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
JP2026512425A (ja) 2023-03-30 2026-04-16 オーエスイー・イミュノセラピューティクス 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof
WO2026066866A1 (zh) * 2024-09-27 2026-04-02 南京宁云生生物科技有限公司 用于预防或治疗溃疡性结肠炎的方法和组合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
KR101351122B1 (ko) * 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
KR100845354B1 (ko) 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항－ｃｔｌａ－4 항체의 용도
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2009111655A (ja) 2007-10-30 2009-05-21 Alaxala Networks Corp ネットワーク管理システム
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
CN105296433B (zh) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
DK3303394T3 (da) * 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
WO2017062797A1 (en) * 2015-10-07 2017-04-13 The University Of North Carolina At Chapel Hill The methods for treatment of tumors
SG10201603721TA (en) * 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
CA3073984A1 (en) 2017-09-21 2019-03-28 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4 antibodies and uses thereof
WO2021098851A1 (en) * 2019-11-20 2021-05-27 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4/ox40 bispecific antibodies and uses thereof
JP2023524669A (ja) * 2020-04-26 2023-06-13 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 改変免疫グロブリン

Also Published As

Publication number Publication date
RU2020111428A3 (es) 2021-10-21
SG11202001604UA (en) 2020-04-29
CA3073984A1 (en) 2019-03-28
EP3684812A1 (en) 2020-07-29
US20200291117A1 (en) 2020-09-17
KR102543719B1 (ko) 2023-06-16
JP2022179611A (ja) 2022-12-02
JP7155270B2 (ja) 2022-10-18
WO2019056281A1 (en) 2019-03-28
CN111406069B (zh) 2022-12-30
US20240343806A1 (en) 2024-10-17
RU2020111428A (ru) 2021-10-21
NZ761454A (en) 2025-10-31
CN111406069A (zh) 2020-07-10
US12054547B2 (en) 2024-08-06
BR112020005496A2 (pt) 2020-09-29
AU2017432728A1 (en) 2020-02-27
US20210188981A1 (en) 2021-06-24
IL304144A (en) 2023-09-01
EP3684812A4 (en) 2021-09-08
US11034764B2 (en) 2021-06-15
JP2021503294A (ja) 2021-02-12
KR20200054220A (ko) 2020-05-19
IL272993A (en) 2020-04-30
AU2017432728B2 (en) 2024-11-07

Similar Documents

Publication Publication Date Title
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
MX2025000260A (es) Proteina de union al antigeno anti-steap1
MX389021B (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MX389090B (es) Anticuerpos anti-pd-l1 novedosos.
CR20200539A (es) Receptores quiméricos de dll3 y métodos para su uso
PH12021551498A1 (en) Activatable masked anti-ctla4 binding proteins
EP3585430A4 (en) TREATMENT OF CANCER WITH ANTIBODIES THAT BIND TO T-CYTOTOXIC T-LYMPHOCYTES ANTIGEN-4 (CTLA-4)
SA518390903B1 (ar) أجسام مضادة لـ جديدة pd-1
IL270743A (en) Monoclonal antibodies to lymphocyte-associated protein - Tcytotoxic 4 (CTLA-4), preparations containing them and their uses
JOP20190236A1 (ar) أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد
ECSP18082207A (es) Neoantígenos y métodos de su uso
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MX384364B (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
MX385456B (es) Anticuerpos cd123 y conjugados de los mismos.
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
BR112020009759A8 (pt) Anticorpos específicos para transcrito 3 semelhante à imunoglobulina (ilt3) e usos dos mesmos
EP3705494A3 (en) Antibodies against frizzled proteins and methods of use thereof
EA201991876A1 (ru) Антитела против фактора d и их применения
MX2025009320A (es) Anticuerpos anti-cd19 novedosos
SA519410534B1 (ar) أجسام مضادة لعامل مساعد لموهن الخلايا الليمفاوية البائية والتائية واستخداماتها
NZ763061A (en) Anti-ox40 antibodies and uses thereof
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
WO2019133902A3 (en) Antibodies and assays for ccl14